These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25417728)

  • 21. Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis.
    Imai H; Kaira K; Naruse I; Hayashi H; Iihara H; Kita Y; Mizusaki N; Asao T; Itoh Y; Sugiyama T; Minato K; Yamada M
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):209-213. PubMed ID: 27900441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
    Chan RT
    Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():7-9. PubMed ID: 29508940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.
    Lin CF; Liu SY; Lo TK; Lee JY; Su PL
    Thorac Cancer; 2022 Feb; 13(3):494-496. PubMed ID: 34918465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evidence on afatinib in patients progressing on a first-line treatment].
    Artal Cortés Á; Gimeno Pelegrín J; Alejandro MÁ
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():19-24. PubMed ID: 27426244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.
    Doesch J; Debus D; Meyer C; Papadopoulos T; Schultz ES; Ficker JH; Brueckl WM
    Lung Cancer; 2016 May; 95():35-8. PubMed ID: 27040849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives.
    Sartori G; Belluomini L; Lombardo F; Avancini A; Trestini I; Vita E; Tregnago D; Menis J; Bria E; Milella M; Pilotto S
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):531-542. PubMed ID: 32529917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of lncRNA BLACAT1 reverses the resistance of afatinib to non-small cell lung cancer via modulating STAT3 signalling.
    Shu D; Xu Y; Chen W
    J Drug Target; 2020 Mar; 28(3):300-306. PubMed ID: 31359792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR inhibition in NSCLC: New findings…. and opened questions?
    Passiglia F; Listì A; Castiglia M; Perez A; Rizzo S; Bazan V; Russo A
    Crit Rev Oncol Hematol; 2017 Apr; 112():126-135. PubMed ID: 28325254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
    Pancewicz-Wojtkiewicz J; Bernatowicz PL
    Anticancer Res; 2017 Jul; 37(7):3543-3546. PubMed ID: 28668844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.
    Passaro A; Pochesci A; Spitaleri G; Catania C; Noberasco C; Del Signore E; de Marinis F
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1283-1288. PubMed ID: 27626838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment.
    Liang H; Liu X; Wang M
    Onco Targets Ther; 2018; 11():6189-6196. PubMed ID: 30288054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
    Ogata H; Okamoto I; Yoshimoto G; Obara T; Ijichi K; Iwama E; Harada T; Akashi K; Nakanishi Y
    Respir Investig; 2017 Mar; 55(2):181-183. PubMed ID: 28274536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.
    Lee VHF
    Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():4-6. PubMed ID: 29508939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.
    Hamada A; Suda K; Koga T; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Uchida T; Mitsudomi T
    Lung Cancer; 2021 Dec; 162():79-85. PubMed ID: 34741886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences.
    Mazzoni F; Petreni P; Perna M; Scotti V; Bongiolatti S; Livi L; Di Costanzo F; Voltolini L
    Tumori; 2018 Dec; 104(6):NP5-NP9. PubMed ID: 29895214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
    Forcella M; Oldani M; Epistolio S; Freguia S; Monti E; Fusi P; Frattini M
    PLoS One; 2017; 12(10):e0187289. PubMed ID: 29088281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
    Passaro A; Pochesci A; Spitaleri G; Catania C; Noberasco C; Del Signore E; de Marinis F
    J Thorac Dis; 2016 Mar; 8(3):E217-20. PubMed ID: 27076973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.
    De Pauw I; Wouters A; Van den Bossche J; Peeters M; Pauwels P; Deschoolmeester V; Vermorken JB; Lardon F
    Pharmacol Ther; 2016 Oct; 166():71-83. PubMed ID: 27373506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Metastatic Brain Tumor from Lung Adenocarcinoma Presenting a Unique Radiographic Pattern during Afatinib Treatment:A Case Report].
    Miyamoto J; Nakagawa T; Hirayama H
    No Shinkei Geka; 2018 Mar; 46(3):213-217. PubMed ID: 29567871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.
    Park CK; Hur JY; Choi CM; Kim TO; Cho HJ; Shin HJ; Lim JH; Choi YD; Kim YC; Oh IJ
    J Korean Med Sci; 2018 Jan; 33(1):e7. PubMed ID: 29215816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.